In conclusion, at a detection limit of 0.08% allelic fraction, our amplicon-based KRAS mutations sequencing assay applied to a large case-control series of plasma samples showed a limited sensitivity of 21.1% for the detection of pancreatic cancer and was not as specific as anticipated. The gene discussed is KRAS; the disease is pancreatic neoplasm.